How Does a Lawrence Livermore Scientist View Pharmacogenetics?
At A Glance Name: Harvey Mohrenweiser Age: 62 Title: Senior Biomedical Scientist; Chair, Program of Education and Workforce Training, Lawrence Livermore National Laboratory Education: PhD in biochemistry from Michigan State University Harvey Mohrenweiser may have been an odd choice to co-author a new pharmacogenomics book. Though he is a geneticist and biochemist by training, Mohren-weiser happens to be a senior scientist at the United States’ premiere nuclear-weapons facility, Lawrence Livermore National Laboratory. But his outsider’s perspective, combined with broad experience and a wealth of contacts, allowed him to offer a unique take on an industry that has been analyzed into homogeneity. In fact, with 8,000 researchers and a $1.5 billion annual budget, Lawrence Livermore devotes just two scientists — Mohrenweiser and a colleague — to study genetic variation and toxicology. SNPtech Reporter caught up with Mohrenweiser recently: Where does pharmacogenomics stand today in toxicology
